The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors

BACKGROUND: Hyperactivation of mTOR pathway and angiogenesis have been implicated in the pathogenesis of neuroendocrine tumors (NETs). Everolimus, an oral inhibitor of mTOR, and sunitinib, an antiangiogenic drug, are effective targeted therapies approved to treat locally advanced/metastatic pancreat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Principais autores: Nuñez, Jose Eduardo, Donadio, Mauro, Filho, Duilio Rocha, Rego, Juliana Florinda, Barros, Milton, Formiga, Maria Nirvana, Lopez, Rossana, Riechelmann, Rachel
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657324/
https://ncbi.nlm.nih.gov/pubmed/31392045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.01.33
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados